Status:
COMPLETED
Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO
Lead Sponsor:
Institut du Cancer de Montpellier - Val d'Aurelle
Conditions:
Prostate Cancer
Bone Metastases
Eligibility:
All Genders
18+ years
Brief Summary
Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of patients with prostate cancer, in the phase of resistance to castration, with symptomatic bone metastases. ...
Detailed Description
Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of patients with prostate cancer, in the phase of resistance to castration, with symptomatic bone metastases. ...
Eligibility Criteria
Inclusion
- All patients who received treatment with XOFIGO in the framework of the AMM, in France since November 2013 are potentially eligible.
Exclusion
- Patients expressing a refusal to use this research data
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2018
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04516707
Start Date
January 1 2016
End Date
May 1 2018
Last Update
August 18 2020
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Icm Val D'Aurelle
Montpellier, Herault, France, 34298
2
ICO Bordeaux
Bordeaux, France
3
UP Clermont Ferrand
Clermont-Ferrand, France
4
Chu Grenoble
Grenoble, France